

16248



DOCKET NO. 17243CIP3(AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant: Chow et al.  
Serial No.: 09/815,362  
Conf. No.: 4078  
Filed: March 21, 2001

For: COMPOUNDS AND METHODS OF TREATMENT HAVING  
AGONIST-LIKE ACTIVITY SELECTIVE AT ALPHA 2B OR 2B/2C  
ADRENERGIC RECEPTORS

Group Art Unit: 1626

Examiner: Rebecca L. Anderson

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as first  
class mail in an envelope addressed to: Mail Stop  
Inventorship, Commissioner for Patents, P.O. Box  
1450, Alexandria, VA 22313-1450 on:

11/10/2003  
(Date of Deposit)

BONNIE FERGUSON  
Printed Name of Person Making Deposit

Bonnie Ferguson  
Signature

11/10/2003  
Date of Signature

For purpose only

PETITION FOR CORRECTION OF INVENTORSHIP

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

010885

1460 130.00

Applicants hereby petition the Commissioner pursuant to 37 CFR 1.48(a) to correct the inventorship in the above-referenced patent application. Through error, inventor Todd M. Heidelbaugh was not named as a joint inventor when this continuation patent application was filed. This error was made by the undersigned without deceptive intent in the haste to file the present application; such haste was exacerbated by the fact the undersigned was simultaneously working without an experienced assistant at the time, a lack that has thankfully since been cured.

Accordingly, Applicants petition the Commissioner to amend the application to set forth the actual inventors. Accompanying this petition is 1) a Statement of Todd M. Heidelbaugh in support of the correction of inventorship, 2) a Declaration by the actual inventors as required by 37 CFR §1.63, and 3) the written consent of the assignee, Allergan, Inc., for such correction of inventorship.

Serial No. 09/815,362  
Docket No. 17243CIP3 (BAR)

Kindly use Deposit Account 01-0885 for the payment of the petition fee and any other cost that may be due as a result of this communication.

Dated: 11/7/08

Respectfully submitted,

By: 

Carlos A. Fisher- T2-7H  
Registration No. 36,510  
Attorney of Record  
ALLERGAN, INC.  
Legal Department  
2525 Dupont Drive  
Irvine, CA. 92612

Telephone: (714) 246-4920  
Facsimile: (714) 246-4249



DOCKET NO. 17243CIP3(AP)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**PATENT**

Applicant: Chow et al.  
Serial No.: 09/815,362  
Conf. No.: 4078  
Filed: March 21, 2001

For: COMPOUNDS AND METHODS OF TREATMENT HAVING  
AGONIST-LIKE ACTIVITY SELECTIVE AT ALPHA 2B OR 2B/2C  
ADRENERGIC RECEPTORS

Group Art Unit: 1626

Examiner: Rebecca L. Anderson

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as first  
class mail in an envelope addressed to: Mail Stop  
Inventorship, Commissioner for Patents, P.O. Box  
1450, Alexandria, VA 22313-1450 on:

11/10/2003  
(Date of Deposit)

BONNIE FERGUSON  
Printed Name of Person Making Deposit

Bonnie Ferguson  
Signature

11/10/2003  
Date of Signature

**CONSENT OF ASSIGNEE TO CORRECTION OF INVENTORSHIP**

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

As owner of the entire right, title, and interest in the above identified patent application, ALLERGAN hereby consents to the correction of inventorship to add Todd M. Heidelbaugh as an inventor in the above-referenced patent application. ALLERGAN'S right to take action pursuant to 37 CFR 3.73 is established in an Assignment from the inventors to ALLERGAN recorded in the Patent and Trademark Office on August 16, 1996 at Reel 8135, Frame 0552.

I, the undersigned, declare that I am authorized to make this appointment on behalf of Allergan, Inc.

Respectfully submitted,

Martin A. Voet  
Martin A. Voet  
Assistant Secretary  
Allergan, Inc.  
2525 Dupont Drive  
Irvine CA 92612